Evidence map›Paper›PMID 35969400›Full record

ArticleJAMA network open2022

Association of Methamphetamine and Opioid Use With Nonfatal Overdose in Rural Communities.

P Todd Korthuis, Ryan R Cook, Canyon A Foot, Gillian Leichtling, Judith I Tsui, Thomas J Stopka, Judith Leahy, Wiley D Jenkins, Robin Baker, Brian Chan and 12 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 96 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Correlates of Rural Naloxone Possession Among People Who Use Drugs: A Multi-State Cross-Sectional Analysis.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 1 country.

P Todd KorthuisSection of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland.
Ryan R CookSection of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland.
Canyon A FootSection of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland.
Gillian LeichtlingComagine Health, Portland, Oregon.
Judith I TsuiSection of General Internal Medicine, Department of Medicine, University of Washington, Seattle.
Thomas J StopkaDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts.
Judith LeahyOregon Health Authority, Portland.
Wiley D JenkinsDepartment of Population Science and Policy, Southern Illinois University School of Medicine, Springfield.
Robin BakerOregon Health & Science University-Portland State University School of Public Health, Portland.
Brian ChanSection of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland.
Heidi M CraneSection of General Internal Medicine, Department of Medicine, University of Washington, Seattle.
Hannah L CooperDepartment of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Judith FeinbergDepartment of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown.
William A ZuleRTI International, Research Triangle Park, North Carolina.
Vivian F GoDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill.
Angela T EstadtDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus.
Robin M NanceSection of General Internal Medicine, Department of Medicine, University of Washington, Seattle.
Gordon S SmithDepartment of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown.
Ryan P WestergaardDivision of Infectious Diseases, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.
Brent Van HamDepartment of Population Science and Policy, Southern Illinois University School of Medicine, Springfield.
Randall BrownDepartment of Family Medicine & Community Health, University of Wisconsin School of Medicine & Public Health, Madison.
April M YoungDepartment of Epidemiology, University of Kentucky, Lexington.
Oregon Health & Science University · USUniversity of Washington · USSouthern Illinois University School of Medicine · USWest Virginia University · USEmory University · USOregon Health Authority · USPortland State University · USRTI International · USThe Ohio State University · USTufts University · USUniversity of Kentucky · USUniversity of North Carolina at Chapel Hill · USUniversity of Wisconsin–Madison · US

Funding

Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Substance use patterns and contexts: impact on epigenetic age and prevention strategies in an HIV clinical care cohortR01DA047045 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Joseph Austin Delaney · 2018 to 2026
$5.1M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Learning from the COVID-19 pandemic to improve emergency management planning for harm reduction services in rural OhioUH3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2019 to 2022
$2.5M
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern AppalachiaUH3DA044823 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZULE, WILLIAM A · 2019 to 2021
$2.4M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UG3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D · 2017 to 2018
$1.6M
Community-based, client-centered prevention homes to address the rural opioid epidemicUG3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2017 to 2018
$1.4M
Kentucky Communities & Researchers Engaging to Halt the Opioid Epidemic-CARE2HOPEUG3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2017 to 2018
$1.3M
NIDA NIH HHS F31 DA054752NIDA NIH HHS K01 DA055130NIDA NIH HHS K23 DA053390NIDA NIH HHS U24 DA048538NIDA NIH HHS UG3 DA044798NIDA NIH HHS UG3 DA044822NIDA NIH HHS UG3 DA044823NIDA NIH HHS UG3 DA044826NIDA NIH HHS UG3 DA044829NIDA NIH HHS UG3 DA044830NIDA NIH HHS UG3 DA044831NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044822NIDA NIH HHS UH3 DA044823NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

Importance: Overdoses continue to increase in the US, but the contribution of methamphetamine use is understudied in rural communities. Objective: To estimate the prevalence of methamphetamine use and its correlates among people who use drugs (PWUD) in rural US communities and to determine whether methamphetamine use is associated with increased nonfatal overdoses. Design, Setting, and Participants: From January 2018 through March 2020, the National Rural Opioid Initiative conducted cross-sectional surveys of PWUD in rural communities in 10 states (Illinois, Kentucky, New Hampshire, Massachusetts, North Carolina, Ohio, Oregon, Vermont, West Virginia, and Wisconsin). Participants included rural PWUD who reported any past-30-day injection drug use or noninjection opioid use to get high. A modified chain-referral sampling strategy identified seeds who referred others using drugs. Data analysis was performed from May 2021 to January 2022. Exposures: Use of methamphetamine alone, opioids alone, or both. Main Outcomes and Measures: Unweighted and weighted prevalence of methamphetamine use, any past-180-day nonfatal overdose, and number of lifetime nonfatal overdoses. Results: Among the 3048 participants, 1737 (57%) were male, 2576 (85%) were White, and 225 (7.4%) were American Indian; the mean (SD) age was 36 (10) years. Most participants (1878 of 2970 participants with any opioid or methamphetamine use [63%]) reported co-use of methamphetamine and opioids, followed by opioids alone (702 participants [24%]), and methamphetamine alone (390 participants [13%]). The estimated unweighted prevalence of methamphetamine use was 80% (95% CI, 64%-90%), and the estimated weighted prevalence was 79% (95% CI, 57%-91%). Nonfatal overdose was greatest in people using both methamphetamine and opioids (395 of 2854 participants with nonmissing overdose data [22%]) vs opioids alone (99 participants [14%]) or methamphetamine alone (23 participants [6%]). Co-use of methamphetamine and opioids was associated with greater nonfatal overdose compared with opioid use alone (adjusted odds ratio, 1.45; 95% CI, 1.08-1.94; P = .01) and methamphetamine use alone (adjusted odds ratio, 3.26; 95% CI, 2.06-5.14; P < .001). Those with co-use had a mean (SD) of 2.4 (4.2) (median [IQR], 1 [0-3]) lifetime overdoses compared with 1.7 (3.5) (median [IQR], 0 [0-2]) among those using opioids alone (adjusted rate ratio, 1.20; 95% CI, 1.01-1.43; P = .04), and 1.1 (2.9) (median [IQR], 0 [0-1]) among those using methamphetamine alone (adjusted rate ratio, 1.81; 95% CI, 1.45-2.27; P < .001). Participants with co-use most often reported having tried and failed to access substance use treatment: 827 participants (44%) for both, 117 participants (30%) for methamphetamine alone, and 252 participants (36%) for opioids alone (χ22 = 33.8; P < .001). Only 66 participants (17%) using methamphetamine alone had naloxone. Conclusions and Relevance: These findings suggest that harm reduction and substance use disorder treatment interventions must address both methamphetamine and opioids to decrease overdose in rural communities.

Indexed as

Drug OverdoseMethamphetamineOpioid-Related DisordersAdultAnalgesics, OpioidCross-Sectional StudiesFemaleHumansMaleRural PopulationAnalgesics, OpioidMethamphetamine

Identifiers

PMID35969400
PMCPMC9379740
OpenAlexW4292367497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.